Andrew A. Hindman's most recent trade in Theravance Biopharma Inc was a trade of 65,000 Ordinary Shares done at an average price of $11.0 . Disclosure was reported to the exchange on Nov. 18, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.02 per share. | 18 Nov 2022 | 65,000 | 409,771 (0%) | 0% | 11.0 | 716,242 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 18 Nov 2022 | 25,057 | 384,714 (0%) | 0% | 10.8 | 271,868 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.34 per share. | 19 Aug 2022 | 25,676 | 473,507 (0%) | 0% | 9.3 | 239,814 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 20,000 | 499,183 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 May 2022 | 3,365 | 479,183 (0%) | 0% | 8.7 | 29,410 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.61 per share. | 18 Feb 2022 | 25,973 | 481,285 (0%) | 0% | 9.6 | 249,601 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2021 | 340,000 | 507,258 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 19 Nov 2021 | 1,350 | 167,258 (0%) | 0% | 8.4 | 11,286 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.05 per share. | 20 Aug 2021 | 17,464 | 167,380 (0%) | 0% | 14.0 | 245,369 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.80 per share. | 20 May 2021 | 942 | 184,844 (0%) | 0% | 17.8 | 16,768 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.79 per share. | 20 Feb 2021 | 3,984 | 184,704 (0%) | 0% | 18.8 | 74,859 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 65,000 | 188,688 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.22 per share. | 20 Aug 2020 | 4,323 | 123,135 (0%) | 0% | 18.2 | 78,765 | Ordinary Shares |
| Theravance Biopharma Inc | Andrew A. Hindman | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2020 | 20,000 | 127,458 (0%) | 0% | 0 | Ordinary Shares |